PMID- 25333812
OWN - NLM
STAT- MEDLINE
DCOM- 20150624
LR  - 20181202
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 11
IP  - 1
DP  - 2015 Jan
TI  - Silencing survivin expression inhibits the tumor growth of non-small-cell lung 
      cancer cells in vitro and in vivo.
PG  - 639-44
LID - 10.3892/mmr.2014.2729 [doi]
AB  - Survivin is a promising anticancer therapeutic target due to its important role 
      in the inhibition of apoptosis of tumor cells. However, little is currently known 
      about its role in non small cell lung cancer (NSCLC). The present study evaluated 
      whether the downregulation of survivin expression would affect cell 
      proliferation, cell cycle distribution, apoptosis and colony formation of NSCLC. 
      A recombinant lentiviral small hairpin RNA (shRNA) expression vector, which 
      specifically targeted survivin, was constructed and transfected into the A549 
      human NSCLC cell line. Quantitative polymerase chain reaction and western 
      blotting were used to determine the mRNA and protein expression levels of 
      survivin, 48 h following the knockdown of survivin expression. Cell 
      proliferation, apoptosis, cell cycle distribution and colony formation were 
      determined following the downregulation of survivin by shRNA. In addition, A549 
      cells were injected into nude mice, and the effects of shRNA targeting the 
      survivin gene on tumor growth were assessed. Downregulation of survivin 
      expression, using the RNA silencing approach in A549 tumor cells, significantly 
      suppressed the proliferation and colony formation ability of the cells, and 
      induced tumor apoptosis in vitro. The nude mice inoculated with A549 cells 
      developed cancer, and treatment with shRNA targeting survivin markedly inhibited 
      the growth of these cancers, with no obvious side effects. The results of the 
      present study suggest that suppression of survivin expression by RNA interference 
      may induce NSCLC apoptosis, and provide a novel approach for anticancer gene 
      therapy.
FAU - Zhang, Kejian
AU  - Zhang K
AD  - Department of Thoracic Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Li, Yang
AU  - Li Y
AD  - Department of Thoracic Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Thoracic Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Gao, Xinliang
AU  - Gao X
AD  - Department of Thoracic Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Zhang, Kewei
AU  - Zhang K
AD  - Department of Thoracic Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20141021
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Survivin)
RN  - EC 3.4.22.- (Caspase 3)
RN  - EC 3.4.22.- (Caspase 8)
SB  - IM
MH  - Animals
MH  - Apoptosis/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*pathology
MH  - Caspase 3/metabolism
MH  - Caspase 8/metabolism
MH  - Cell Cycle/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Disease Models, Animal
MH  - Female
MH  - *Gene Silencing
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/*genetics
MH  - Lung Neoplasms/*genetics/*pathology
MH  - Mice
MH  - Neoplastic Stem Cells/metabolism
MH  - RNA Interference
MH  - RNA, Small Interfering/genetics
MH  - Survivin
MH  - Tumor Burden/genetics
MH  - Xenograft Model Antitumor Assays
EDAT- 2014/10/22 06:00
MHDA- 2015/06/25 06:00
CRDT- 2014/10/22 06:00
PHST- 2014/01/26 00:00 [received]
PHST- 2014/09/18 00:00 [accepted]
PHST- 2014/10/22 06:00 [entrez]
PHST- 2014/10/22 06:00 [pubmed]
PHST- 2015/06/25 06:00 [medline]
AID - 10.3892/mmr.2014.2729 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Jan;11(1):639-44. doi: 10.3892/mmr.2014.2729. Epub 2014 Oct 21.